Skip to main content

Table 1 Patient Characteristics

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Variables Startification Over all BDca GBca
Spieces of cancer   42 27 15
Sex (male/female) (24/18) (17/10) (7/8)
Age   66.5 ± 7.5 64.8 ± 8.2 69.5 ± 4.7
ECOG PS (0/1/2) (36/4/2) (22/4/1) (14/0/1)
Disease Status (unresectable/postoperative recurrence) (26/16) (15/12) (11/4)
Disease extension locally advanced (primary) 26 15 11
  local recurrence 7 7 0
  liver metastasis 9 4 5
  lung metastasis 4 3 1
  lymphnode metastasis 11 4 7
  miscellaneous metastasis 5 5 0
Tumor marker carcinoembryonic antigen (CEA) 16.7 ± 60.7 6.4 ± 17.2 36.7 ± 100.5
  CA19-9 3035.5 ± 9507.6 4495.3 ± 11688.8 407.9 ± 587.2
Previous chemotherapy (yes/no) (4/38) (3/24) (1/14)
  1. Abbreveations
  2. BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status